Sangamo Therapeutics Inc (SGMO) concluded trading on Wednesday at a closing price of $0.50, with 4.25 million shares of worth about $2.12 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -75.61% during that period and on May 21, 2025 the price saw a gain of about 0.18%. Currently the company’s common shares owned by public are about 245.40M shares, out of which, 234.62M shares are available for trading.
Stock saw a price change of 14.16% in past 5 days and over the past one month there was a price change of -35.59%. Year-to-date (YTD), SGMO shares are showing a performance of -50.98% which decreased to -23.03% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.30 but also hit the highest price of $3.18 during that period. The average intraday trading volume for Sangamo Therapeutics Inc shares is 7.07 million. The stock is currently trading -21.69% below its 20-day simple moving average (SMA20), while that difference is down -30.77% for SMA50 and it goes to -58.17% lower than SMA200.
Sangamo Therapeutics Inc (NASDAQ: SGMO) currently have 245.40M outstanding shares and institutions hold larger chunk of about 21.55% of that.
The stock has a current market capitalization of $122.70M and its 3Y-monthly beta is at 1.26. It has posted earnings per share of -$0.38 in the same period. It has Quick Ratio of 0.76 while making debt-to-equity ratio of 5.07. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for SGMO, volatility over the week remained 8.74% while standing at 11.36% over the month.
Stock’s fiscal year EPS is expected to rise by 25.07% while it is estimated to increase by 3.11% in next year. EPS is likely to grow at an annualized rate of 20.66% for next 5-years, compared to annual growth of 10.57% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Truist on December 13, 2024 offering a Buy rating for the stock and assigned a target price of $7 to it. Coverage by H.C. Wainwright stated Sangamo Therapeutics Inc (SGMO) stock as a Buy in their note to investors on December 10, 2024, suggesting a price target of $10 for the stock. On November 03, 2023, RBC Capital Mkts Downgrade their recommendations, while on April 28, 2023, BofA Securities Downgrade their ratings for the stock with a price target of $1.50. Stock get an Outperform rating from Wedbush on February 27, 2023.
